See more : Alla Public Company Limited (ALLA.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Annovis Bio, Inc. (ANVS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Annovis Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- TPC Power Holding Public Company Limited (TPCH.BK) Income Statement Analysis – Financial Results
- Toyota Industries Corporation (TYIDF) Income Statement Analysis – Financial Results
- SCWorx Corp. (WORX) Income Statement Analysis – Financial Results
- Arshiya Limited (ARSHIYA.NS) Income Statement Analysis – Financial Results
- Juma Technology Corp. (JUMT) Income Statement Analysis – Financial Results
Annovis Bio, Inc. (ANVS)
About Annovis Bio, Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 38.79M | 16.52M | 8.48M | 3.05M | 776.26K | 111.61K | 273.37K |
| General & Administrative | 6.24M | 9.00M | 6.06M | 3.59M | 829.37K | 602.33K | 409.06K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.24M | 9.00M | 6.06M | 3.59M | 829.37K | 602.33K | 409.06K |
| Other Expenses | 0.00 | 0.00 | -36.75K | -1.16M | -735.08K | 0.00 | 0.00 |
| Operating Expenses | 45.04M | 25.51M | 14.50M | 5.48M | 870.55K | 713.94K | 682.43K |
| Cost & Expenses | 45.04M | 25.51M | 14.50M | 5.48M | 870.55K | 713.94K | 682.43K |
| Interest Income | 667.90M | 182.71K | 13.34K | 47.23K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 47.23M | 0.00 | 66.00 | 84.00 |
| Depreciation & Amortization | 1.00 | 25.51M | 14.54M | 6.64M | 1.61M | 713.94K | 682.43K |
| EBITDA | -45.04M | 0.00 | 0.00 | 0.00 | 0.00 | 66.00 | 84.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -45.04M | -25.51M | -14.54M | -6.64M | -1.61M | -713.94K | -682.43K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -11.17M | 182.71K | 50.09K | 1.18M | 614.64K | 66.00 | 84.00 |
| Income Before Tax | -56.20M | -25.33M | -14.49M | -5.46M | -990.98K | -713.87K | -682.35K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -182.71K | -50.09K | -1.20M | -694.14K | -132.00 | -682.43K |
| Net Income | -56.20M | -25.15M | -14.44M | -4.26M | -296.84K | -713.87K | -682.35K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -6.23 | -3.08 | -1.89 | -0.67 | -0.07 | -0.16 | -0.16 |
| EPS Diluted | -6.23 | -3.08 | -1.89 | -0.67 | -0.07 | -0.16 | -0.16 |
| Weighted Avg Shares Out | 9.02M | 8.16M | 7.63M | 6.31M | 4.50M | 4.40M | 4.39M |
| Weighted Avg Shares Out (Dil) | 9.02M | 8.16M | 7.63M | 6.31M | 4.50M | 4.40M | 4.39M |
Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update
BERWYN, Pa. , Aug. 8, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced second quarter financial results for the quarter ended June 30, 2022, and reviewed...
Annovis Bio to Participate on Alzheimer's Association International Conference Panel
The Panel will be Moderated by Jeffrey Cummings, MD, ScD, and Krista Lanctôt, Ph.D. BERWYN, Pa.
Annovis Bio to Present at the Alzheimer's Association International Conference
Maria Maccecchini, Ph.D., Founder, President, and CEO, will be participating on a panel discussing the Systems Biology of Alzheimer's Disease moderated by Jeffrey Cummings, MD, ScD, and Krista Lanctôt, Ph.D.
FDA Gives Green Signal To Annovis Bio's Parkinson's Trial With Buntanetap
Annovis Bio Inc (NYSE: ANVS) received notice from the FDA that the Phase 3 clinical study with buntanetap in early Parkinson's patients may proceed. The FDA accepted the final protocol and the clinical development plan and approved using the company's new large-scale.
Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease
FDA indicates the Company may proceed with the Phase 3 clinical study of buntanetap for the treatment of Parkinson's disease BERWYN, Pa. , July 7, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical...
Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections
Annovis Bio's Current Intellectual Property Portfolio Covers the Use of Buntanetap, the Company's Lead Compound, to Treat Neurodegenerative Diseases With this Recent Filing, the Company Seeks Protection for Buntanetap to Treat Infection-Dependent Neurological Injuries BERWYN, Pa. , June 9, 2022...
Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update
Berwyn, Pennsylvania--(Newsfile Corp. - May 4, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced first quarter financial results for the quarter ended March 31, 2022, and provided...
Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging
Collaboration to Develop Pharmacodynamic Biomarkers for BuntanetapBerwyn, Pennsylvania--(Newsfile Corp. - April 28, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today a Cooperative Research and Development Agreement (CRADA)...
Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease
Berwyn, Pennsylvania--(Newsfile Corp. - April 11, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, is pleased to participate in World Parkinson's Day to promote greater awareness of how Parkinson's...
Annovis Bio to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
Berwyn, Pennsylvania--(Newsfile Corp. - March 23, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced the company has been invited to present at the 2022 Virtual Growth Conference,...
Source: https://incomestatements.info
Category: Stock Reports